What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 24 months?
One-OffSağlık ve TıpBilim1ay
Manifold MarketsKYC yokDoğrulanmış sonuçlanma verisiOrta düzey kalibreGüncel topluluk tahmini70-79% 39.3%7 seçenek arasında lider
Tahminciler
15
Soru türü
multiple choice
Yöntem
Play-money forecasting platform
Kaynak türü
Tahmin
7g Değişim
+17.5 pts
Piyasa verileri
15 saat önce güncellendi
Guncelligini yitirmis15 Mar 24 21:17 UTC2 Ara 26 07:59 UTC
Trendler
İlgili Piyasalar
Bağlam için ilgili sorular; eşdeğer sözleşmelerin karşılaştırması değildir.
What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWill molecular jackhammers have at least 50% tumour-free efficacy in Phase 2 clinical trials?
Manifold MarketsHow many human screwworm cases will be reported in the United States in 2026?
KalshiWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
KalshiWhich countries will have an Ebola case in 2026?
PolymarketNew pandemic in 2026? [Polymarket]
Manifold MarketsKurallar
The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.
- Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
- Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2025).
- Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
- 1Day Sooner has an R21 Status Report available here that may be useful.
- More malaria-related questions can be found on our Manifold account here.